RPG Life Sciences Board approves FY26 results, ₹24 dividend, new director

RPG Life Sciences Ltd's Board of Directors, at its meeting held on April 29, 2026, approved the audited financial results (standalone and consolidated) for the quarter and year ended March 31, 2026. The Board recommended a dividend of ₹24 per equity share (300% on face value of ₹8) for FY 2025-26, subject to shareholder approval. Additionally, Dr. Pratit Samdani was appointed as an Additional Non-Executive Independent Director for a five-year term from April 29, 2026. The Board also approved an amendment to the Code of fair disclosure and insider trading procedures. The trading window for the company's securities will open 48 hours after the results declaration.